Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Summit Therapeutics (SMMT) FCF Margin (2016 - 2022)

Summit Therapeutics filings provide 7 years of FCF Margin readings, the most recent being 3879.55% for Q3 2022.

  • Quarterly FCF Margin fell 207962.0% to 3879.55% in Q3 2022 from the year-ago period, while the trailing twelve-month figure was 20823.18% through Jun 2023, down 1731550.0% year-over-year, with the annual reading at 5986.67% for FY2022, 195720.0% down from the prior year.
  • FCF Margin hit 3879.55% in Q3 2022 for Summit Therapeutics, up from 8302.13% in the prior quarter.
  • Across five years, FCF Margin topped out at 2642.07% in Q1 2020 and bottomed at 33903.51% in Q2 2021.
  • Average FCF Margin over 5 years is 5705.6%, with a median of 3879.55% recorded in 2022.
  • The largest annual shift saw FCF Margin tumbled -2292645bps in 2021 before it skyrocketed 2560138bps in 2022.
  • Summit Therapeutics' FCF Margin stood at 645.22% in 2018, then crashed by -706bps to 3908.78% in 2019, then dropped by -11bps to 4335.68% in 2020, then grew by 15bps to 3704.78% in 2021, then decreased by -5bps to 3879.55% in 2022.
  • Per Business Quant, the three most recent readings for SMMT's FCF Margin are 3879.55% (Q3 2022), 8302.13% (Q2 2022), and 7744.8% (Q1 2022).